載入中
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
收盤時
US$1.02
+US$0.02 · +2.00%
盤後
US$1.05
+US$0.03 · +2.94%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
日內區間
目前US$1.02
52週區間
目前US$1.02
盤中時間採用ET。市場資料可能有所延遲。
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
日內區間
目前US$1.02
52週區間
目前US$1.02
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 2521萬 USD | 5229.5萬 USD | 4475.6萬 USD | 1720萬 USD | 24.3萬 USD |
| 銷貨成本 | 531.7萬 USD | — | 9440.3萬 USD | 173.3萬 USD | 38.7萬 USD |
| 毛利 | 1989.3萬 USD | 5229.5萬 USD | −4964.7萬 USD | 1546.7萬 USD | −14.4萬 USD |
| 研究與開發 | 9443.3萬 USD | 1.09億 USD | 9440.3萬 USD | 4313.9萬 USD | 1447.8萬 USD |
| 銷售、一般及管理費用 | 2679萬 USD | 3201.7萬 USD | 2884.5萬 USD | 1870.1萬 USD | 971.2萬 USD |
| 營業費用 | 1.16億 USD | 1.41億 USD | 2884.5萬 USD | 6010.7萬 USD | 2380.3萬 USD |
| 利息收入 | 947萬 USD | 1472.2萬 USD | 1546.8萬 USD | 341.9萬 USD | 4.3萬 USD |
| 利息支出 | — | — | — | 9.8萬 USD | 30.2萬 USD |
| 折舊和攤銷 | 531.7萬 USD | 540.7萬 USD | 420.7萬 USD | 173.3萬 USD | 38.7萬 USD |
| 營業利益 | −9601.3萬 USD | −8890.1萬 USD | −7849.2萬 USD | −4464萬 USD | −2394.7萬 USD |
| 淨利 | −8786.8萬 USD | −7805.8萬 USD | −6825.5萬 USD | −4359.3萬 USD | −2144.2萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$14.50
上漲空間 1321.57%AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
